202 related articles for article (PubMed ID: 37340065)
21. Diffuse midline glioma H3 K27M-mutant in adults: A report of six cases and literature review.
Alzoubi H; Maraqa B; Hasasna N; Giangaspero F; Antonelli M; Gianno F; Arcella A; Al-Hussaini M
Clin Neuropathol; 2021; 40(2):108-117. PubMed ID: 33191898
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive assessment of H3 K27M mutational status in diffuse midline gliomas by using apparent diffusion coefficient measurements.
Chen H; Hu W; He H; Yang Y; Wen G; Lv X
Eur J Radiol; 2019 May; 114():152-159. PubMed ID: 31005167
[TBL] [Abstract][Full Text] [Related]
23. High frequency of H3 K27M mutations in adult midline gliomas.
Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J
J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375
[TBL] [Abstract][Full Text] [Related]
24. An adult case of diffuse midline glioma with H3 K27M mutation.
Tu JH; Piao YS; Lu DH; Wang LM; Liu L; Bai DY; Han HW; Lin YK; Zhong S
Neuropathology; 2020 Dec; 40(6):627-631. PubMed ID: 32954563
[TBL] [Abstract][Full Text] [Related]
25. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
Auffret L; Ajlil Y; Tauziède-Espariat A; Kergrohen T; Puiseux C; Riffaud L; Blouin P; Bertozzi AI; Leblond P; Blomgren K; Froelich S; Picca A; Touat M; Sanson M; Beccaria K; Blauwblomme T; Dangouloff-Ros V; Boddaert N; Varlet P; Debily MA; Grill J; Castel D
Acta Neuropathol; 2023 Dec; 147(1):2. PubMed ID: 38066305
[TBL] [Abstract][Full Text] [Related]
26. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant.
Maeda S; Ohka F; Okuno Y; Aoki K; Motomura K; Takeuchi K; Kusakari H; Yanagisawa N; Sato S; Yamaguchi J; Tanahashi K; Hirano M; Kato A; Shimizu H; Kitano Y; Yamazaki S; Yamashita S; Takeshima H; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
Acta Neuropathol Commun; 2020 Feb; 8(1):8. PubMed ID: 32019606
[TBL] [Abstract][Full Text] [Related]
27. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A; de Groot J; Dixit KS; Graber JJ; Haggiagi AM; Harrison RA; Kheradpour A; Kilburn LB; Kurz SC; Lu G; MacDonald TJ; Mehta M; Melemed AS; Nghiemphu PL; Ramage SC; Shonka N; Sumrall A; Tarapore RS; Taylor L; Umemura Y; Wen PY
J Clin Oncol; 2024 May; 42(13):1542-1552. PubMed ID: 38335473
[TBL] [Abstract][Full Text] [Related]
28. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.
van den Bent M; Saratsis AM; Geurts M; Franceschi E
Neuro Oncol; 2024 May; 26(Supplement_2):S110-S124. PubMed ID: 38102230
[TBL] [Abstract][Full Text] [Related]
29. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.
Chai RC; Zhang YW; Liu YQ; Chang YZ; Pang B; Jiang T; Jia WQ; Wang YZ
Acta Neuropathol Commun; 2020 Mar; 8(1):40. PubMed ID: 32228694
[TBL] [Abstract][Full Text] [Related]
30. Impact of H3.3 K27M Mutation on Prognosis and Survival of Grade IV Spinal Cord Glioma on the Basis of New 2016 World Health Organization Classification of the Central Nervous System.
Yi S; Choi S; Shin DA; Kim DS; Choi J; Ha Y; Kim KN; Suh CO; Chang JH; Kim SH; Yoon DH
Neurosurgery; 2019 May; 84(5):1072-1081. PubMed ID: 29718432
[TBL] [Abstract][Full Text] [Related]
31. Diffuse midline glioma with H3 K27M mutation: a comparison integrating the clinical, radiological, and molecular features between adult and pediatric patients.
Jiang H; Yang K; Ren X; Cui Y; Li M; Lei Y; Lin S
Neuro Oncol; 2020 May; 22(5):e1-e9. PubMed ID: 31504810
[TBL] [Abstract][Full Text] [Related]
32. A longitudinally extensive H3 K27M-mutant diffuse midline glioma in an elderly patient clinically mimicking central nervous system inflammation: a case report.
Babarczy K; Reisz Z; Szabo E; Rajda C; Vecsei L; Bodi I; Klivenyi P; Hortobagyi T; Szalardy L
Folia Neuropathol; 2020; 58(4):377-385. PubMed ID: 33480242
[TBL] [Abstract][Full Text] [Related]
33. Multimodal MR imaging signatures to identify brain diffuse midline gliomas with H3 K27M mutation.
Su X; Liu Y; Wang H; Chen N; Sun H; Yang X; Wang W; Zhang S; Wan X; Tan Q; Yue Q; Gong Q
Cancer Med; 2022 Feb; 11(4):1048-1058. PubMed ID: 34953060
[TBL] [Abstract][Full Text] [Related]
34. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
Vuong HG; Ngo TNM; Le HT; Dunn IF
J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
[TBL] [Abstract][Full Text] [Related]
35. Histone H3 K27M mutations in adult cerebellar high-grade gliomas.
Nakata S; Nobusawa S; Yamazaki T; Osawa T; Horiguchi K; Hashiba Y; Yaoita H; Matsumura N; Ikota H; Hirato J; Yoshimoto Y; Yokoo H
Brain Tumor Pathol; 2017 Jul; 34(3):113-119. PubMed ID: 28547652
[TBL] [Abstract][Full Text] [Related]
36. Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis.
Aboian MS; Tong E; Solomon DA; Kline C; Gautam A; Vardapetyan A; Tamrazi B; Li Y; Jordan CD; Felton E; Weinberg B; Braunstein S; Mueller S; Cha S
AJNR Am J Neuroradiol; 2019 Nov; 40(11):1804-1810. PubMed ID: 31694820
[TBL] [Abstract][Full Text] [Related]
37. Automated machine learning based on radiomics features predicts H3 K27M mutation in midline gliomas of the brain.
Su X; Chen N; Sun H; Liu Y; Yang X; Wang W; Zhang S; Tan Q; Su J; Gong Q; Yue Q
Neuro Oncol; 2020 Mar; 22(3):393-401. PubMed ID: 31563963
[TBL] [Abstract][Full Text] [Related]
38. ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
Arrillaga-Romany I; Lassman A; McGovern SL; Mueller S; Nabors B; van den Bent M; Vogelbaum MA; Allen JE; Melemed AS; Tarapore RS; Wen PY; Cloughesy T
Neuro Oncol; 2024 May; 26(Supplement_2):S173-S181. PubMed ID: 38445964
[TBL] [Abstract][Full Text] [Related]
39. A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations.
Nakano Y; Yamasaki K; Sakamoto H; Matsusaka Y; Kunihiro N; Fukushima H; Inoue T; Honda-Kitahara M; Hara J; Yoshida A; Ichimura K
Brain Tumor Pathol; 2019 Oct; 36(4):162-168. PubMed ID: 31254135
[TBL] [Abstract][Full Text] [Related]
40. Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.
Low JT; Wang SH; B Peters K
CNS Oncol; 2021 Jun; 10(2):CNS71. PubMed ID: 33908265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
